A Phase 2a, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis

Trial Profile

A Phase 2a, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs VT 1161 (Primary) ; Fluconazole
  • Indications Vulvovaginal candidiasis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Viamet Pharmaceuticals
  • Most Recent Events

    • 29 Jul 2015 According to Viamet Pharmaceuticals media release, the data from this trial will be presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting 2015.
    • 24 Apr 2015 Results will be presented at the European Congress for Clinical Microbiology and Infectious Diseases Conference 2015, according to a Viamet Pharmaceuticals media release.
    • 12 Feb 2015 Results published in a Viamet Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top